| Aug 13 |
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Aug 12 |
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants
|
| Aug 9 |
Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants
|
| Aug 1 |
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
|
| Jul 12 |
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
|
| Jun 14 |
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
|
| Jun 6 |
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
|
| Jun 3 |
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
|
| May 29 |
Zura Bio Announces Participation in June Investor Conferences
|
| May 24 |
Zura Bio files to sell 41.6M Class A ordinary shares for holders
|
